Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
Psychiatry and Clinical Neurosciences
|
November 6, 2025
Ensuring generalizability and clinical utility in mental health care applications: Robust artificial intelligence-based treatment predictions in diverse psychosis populations
Fiona Coutts, Sergio Mena, Esin Ucur, et al.
The Journal of Behavioral Health Services & Research
|
February 5, 2008
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia
Sandra G Resnick, Robert A Rosenheck, Jose M Canive, et al.
The Australian and New Zealand Journal of Psychiatry
|
April 28, 2007
AKT1 and neurocognition in schizophrenia
Andrea Poyastro Pinheiro, Richard S E Keefe, Tara Skelly, et al.
The American Journal of Psychiatry
|
August 18, 2010
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression
Jie Huang, Roy H Perlis, Phil H Lee, et al.
Schizophrenia Research
|
November 18, 2008
Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function
Leah Kleinman, Jeffrey Lieberman, Sanjay Dube, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
July 30, 2010
Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case-control and family based study designs
Clement C Zai, Mirko Manchia, Vincenzo De Luca, et al.
The American Journal of Psychiatry
|
December 8, 2006
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia
Robert A Rosenheck, Douglas L Leslie, Jody Sindelar, et al.
Schizophrenia Bulletin
|
August 23, 2021
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Anissa Abi-Dargham, Jonathan A Javitch, Mark Slifstein, et al.
Neuroimage. Clinical
|
March 11, 2019
A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms
Leah M Fleming, Daniel C Javitt, Cameron S Carter, et al.
Schizophrenia Research
|
December 16, 2011
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
Daniel C Javitt, Robert W Buchanan, Richard S E Keefe, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
Psychiatry and Clinical Neurosciences
|
November 6, 2025
Ensuring generalizability and clinical utility in mental health care applications: Robust artificial intelligence-based treatment predictions in diverse psychosis populations
Fiona Coutts, Sergio Mena, Esin Ucur, et al.
The Journal of Behavioral Health Services & Research
|
February 5, 2008
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia
Sandra G Resnick, Robert A Rosenheck, Jose M Canive, et al.
The Australian and New Zealand Journal of Psychiatry
|
April 28, 2007
AKT1 and neurocognition in schizophrenia
Andrea Poyastro Pinheiro, Richard S E Keefe, Tara Skelly, et al.
The American Journal of Psychiatry
|
August 18, 2010
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression
Jie Huang, Roy H Perlis, Phil H Lee, et al.
Schizophrenia Research
|
November 18, 2008
Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function
Leah Kleinman, Jeffrey Lieberman, Sanjay Dube, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
July 30, 2010
Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case-control and family based study designs
Clement C Zai, Mirko Manchia, Vincenzo De Luca, et al.
The American Journal of Psychiatry
|
December 8, 2006
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia
Robert A Rosenheck, Douglas L Leslie, Jody Sindelar, et al.
Schizophrenia Bulletin
|
August 23, 2021
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Anissa Abi-Dargham, Jonathan A Javitch, Mark Slifstein, et al.
Neuroimage. Clinical
|
March 11, 2019
A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms
Leah M Fleming, Daniel C Javitt, Cameron S Carter, et al.
Schizophrenia Research
|
December 16, 2011
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
Daniel C Javitt, Robert W Buchanan, Richard S E Keefe, et al.
Page
of 7